Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

KPTI - Karyopharm Therapeutics Inc. So'nggi... | Finranks

Home

KPTI

K

Karyopharm Therapeutics Inc. (KPTI)

NMS – Real vaqt narxi. Valyuta: USD

5.48

-0.09 (-1.62%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

5.29

-0.19 (-3.47%)

Bozordan keyin: Mar 27, 2026, 7:46 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Karyopharm: Putting The Phase 3 Trial In Context

Karyopharm: Putting The Phase 3 Trial In Context

Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement, while showing a promising, though immature, overall survival signal. Dire cash position persists despite a $30 million private placement; runway extends only into Q2 2026, with existential funding risks looming.

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Karyopharm Therapeutics said on Tuesday its ‌oncology therapy showed a statistically significant improvement in spleen ⁠volume in a late‑stage trial in patients with a rare blood cancer, one of ‌the ⁠study's main goals.

Karyopharm Announces $30 Million Private Placement with RA Capital

Karyopharm Announces $30 Million Private Placement with RA Capital

NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full.

Videolar

No Data

There is no data to display

Press-relizlar

Karyopharm Announces $30 Million Private Placement with RA Capital

Karyopharm Announces $30 Million Private Placement with RA Capital

NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full.

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib – – Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib – – Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – – No New Safety Signals Identified – – Karyopharm will Meet with the FDA to Discuss the Totality of the Data and Potential sNDA Filing – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees.

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Revenue was $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $115 Million for Full Year 2025 – – Company Provides Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.